RBMXL2

Across TCGA pan-cancer cohorts, RBMXL2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RBMXL2 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher RBMXL2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RBMXL2 expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.

ESCA, COAD, and GBM are the cancer types where RBMXL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	36	view →
COAD	OS	Median	IV	0.089	0.649	.005	15	view →
GBM	OS	Median	All	0.020	0.416	<.001	12	view →
SCLC	OS	Median	All	0.687	0.231	.028	11	view →
CESC	DFS	Median	III,IV	0.240	0.726	.015	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RBMXL2–ESCA (OS)

Open the ESCA breakdown →